IRIS
BOGGIANI, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 261
EU - Europa 233
AS - Asia 88
Continente sconosciuto - Info sul continente non disponibili 1
Totale 583
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 260
IE - Irlanda 94
CN - Cina 69
SE - Svezia 62
IT - Italia 37
DE - Germania 17
SG - Singapore 14
FI - Finlandia 6
CZ - Repubblica Ceca 5
RU - Federazione Russa 4
BE - Belgio 3
IN - India 3
GB - Regno Unito 2
NL - Olanda 2
TR - Turchia 2
A1 - Anonimo 1
CA - Canada 1
ES - Italia 1
Totale 583
Salva come PNG Salva come JPEG
Città #
Chandler 94
Dublin 94
Shanghai 27
Beijing 26
Ashburn 16
Bremen 12
New York 12
Princeton 12
Seattle 12
Ann Arbor 11
Dearborn 8
Des Moines 8
Wilmington 8
Ravenna 7
Singapore 7
Helsinki 6
Parma 5
Ardea 4
Cascina 4
Olomouc 4
Boardman 3
Brussels 3
Bologna 2
Falls Church 2
Fremont 2
Los Angeles 2
Nanchang 2
Pavia 2
Rio Saliceto 2
Rome 2
Amsterdam 1
Brooklyn 1
Edinburgh 1
Fairfield 1
Frankfurt am Main 1
Guangzhou 1
Hebei 1
Huizen 1
Izmir 1
Jiaxing 1
Kocaeli 1
Kunming 1
London 1
Madrid 1
Milan 1
Modena 1
Montreal 1
Moscow 1
Piacenza 1
Prague 1
Pune 1
Redwood City 1
Rockville 1
Shenyang 1
Shenzhen 1
Stockholm 1
Taglio Di Po 1
Taizhou 1
Tianjin 1
Woodbridge 1
Totale 429
Salva come PNG Salva come JPEG
Nome #
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 58
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 58
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 53
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 50
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 47
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 46
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 43
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 42
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations 38
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 37
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 34
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 27
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 26
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 24
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study 20
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 5
Totale 608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.864
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 2 1 0 0 4 6 2 2 1 34 8 0
2020/202143 2 5 0 3 3 6 9 7 4 2 1 1
2021/202244 0 1 5 0 2 0 3 4 1 0 1 27
2022/2023315 25 34 19 22 34 33 2 23 112 1 8 2
2023/2024137 2 14 1 2 3 22 10 22 4 18 22 17
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 608